Xtl Biopharmaceuticals Operating Income Growth & History (XTLB)

Xtl Biopharmaceuticals's operating income was −$1.4M for fiscal 2025.

View full Xtl Biopharmaceuticals company overview

Xtl Biopharmaceuticals annual operating income history

Xtl Biopharmaceuticals annual operating income

Fiscal yearPeriod endedOperating incomeChangeGrowth
20252025-12-31−$1.4M$792,000
20242024-12-31−$2.2M−$1.4M
20232023-12-31−$765,000$115,000
20222022-12-31−$880,000$151,000
20212021-12-31−$1.0M−$83,000
20202020-12-31−$948,000−$106,000
20192019-12-31−$842,000−$49,000
20182018-12-31−$793,000$453,000
20172017-12-31−$1.2M$1.3M
20162016-12-31−$2.6M$1.1M
20152015-12-31−$3.6M

Xtl Biopharmaceuticals operating income trends

Over the last five fiscal years, Xtl Biopharmaceuticals's operating income decreased from −$948,000 to −$1.4M, a change of −$432,000. The latest reported quarter, Q4 2024, shows −$812,000.

About the metric

What operating income means

Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.

Calculation and source

SEC-reported operating income

TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Xtl Biopharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about XTLB yet. Start the conversation.

Write the first post